Novartis Secures FDA Priority Review For Brolucizumab Thanks To PRV
Executive Summary
Novartis used a priority review voucher for brolucizumab, positioning the eye drug for a US launch in late 2019 if the FDA review goes smoothly.
Topics
- Therapy Areas
- Ophthalmic
- Subjects
- Drug Review
- Business Strategies
- Biologics
- Commercial
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125067
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC125067
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.